KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.96

Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.

Tiantian Tang, Jingxuan Wang, Tao Sun, Lina Zhang, Fanfan Li, Bing Zhao, Guohui Han, Zhongsheng Tong, Hua Yang, Yongmei Yin, Xiangshun Kong, Ying Wang, Jianyun Nie, Lixia Ma, Yongqiang Zhang, Jing Luo, Changping Shan, Jing Yao, Shisheng Tan, Xiaoling Ling, Hongmei Sun, Huihui Li, Li Ma, Tao Zhou, Yunjiang Liu, Yixin Qi, Zhenchuan Song, Yuntao Li, Chao Yang, Tianli Hui, Meiqi Wang, Haoqi Wang, Xi Zhang, Wenhui Zhao, Yanhui Li, Mengmeng Li, Ying Xin, Xuan Luo, Deliang Yin, Hongmei Luo, Huan Liu, Qianyun Lu, Jing Yuan, Cuizhi Geng, Qingyuan Zhang

Biomol Biomed 10.17305/bb.2026.14334

PMID42483812
PMCID-
DOI10.17305/bb.2026.14334
发表日期2026-07-22
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

SYHX2011 is a novel albumin-bound paclitaxel formulation designed to simplify drug preparation and reduce skin rash by replacing most non-particulate human serum albumin with mannitol and sucrose. This exploratory analysis evaluated updated survival outcomes after extended follow-up of a multicenter, randomized, double-blind, phase III trial comparing SYHX2011 with approved albumin-bound paclitaxel (PAB; Keaili®) in patients with unresectable locally advanced or metastatic breast cancer. Overall, 459 patients were randomized 1:1 to receive SYHX2011 or PAB. At the December 29, 2025 data cutoff, median follow-up was 25.2 and 25.0 months, respectively. Median progression-free survival (PFS) was 7.6 months with SYHX2011 and 5.6 months with PAB (p=0.028; hazard ratio [HR]=0.79, 95% confidence interval [CI]: 0.63-1.01). Median overall survival (OS) was not reached with SYHX2011 and was 24.3 months with PAB (p=0.11; HR=0.84, 95% CI: 0.64-1.11). Descriptive trends toward longer PFS and OS with SYHX2011 were observed across hormone receptor-positive, triple-negative, first-line, and later-line subgroups. Although OS data remain immature and subgroup findings require cautious interpretation, the updated results support continued clinical evaluation of SYHX2011 as an albumin-bound paclitaxel option for advanced breast cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。